Daniel Li - Concepedia

Author

Daniel Li

The Ohio State University ORCID

Also Known As

Camille Lemieux, D Li, Daniel D. Li, Daniel Li

115

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

The Ohio State University Cornell University Fred Hutch Cancer Center University of Washington Harvard University

About

Daniel Li is an author at The Ohio State University specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	501
2	Health Sciences	3	3	74
3	Public Health	2	2	65
4	Natural Sciences	1	1	41
5	Allergy	1	1	80

Daniel Li

Publications

5.9K

Citations

H-Index

Page 1

	Year	Citations
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia Richard R. Furman, Jeff P. Sharman, Steven Coutré, New England Journal of Medicine	2014	1.7K
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma Ajay K. Gopal, Brad S. Kahl, Sven de Vos, New England Journal of Medicine	2014	1K
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib Cameron J. Turtle, Kevin A. Hay, Laïla‐Aïcha Hanafi, Journal of Clinical Oncology	2017	649
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia Jennifer R. Brown, John C. Byrd, Steven Coutré, Blood	2014	583
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy Kevin A. Hay, Jordan Gauthier, Alexandre V. Hirayama, Blood	2019	389
CD19 CAR T cell product and disease attributes predict leukemia remission durability Olivia Finney, Hannah Brakke, Stephanie Rawlings-Rhea, Journal of Clinical Investigation	2019	335
Effectiveness of Ultraviolet-C Light and a High-Level Disinfection Cabinet for Decontamination of N95 Respirators Jennifer L. Cadnum, Daniel Li, Sarah N. Redmond, Pathogens and Immunity	2020	119
Second Interim Analysis of a Phase 3 Study of Idelalisib (ZYDELIG®) Plus Rituximab (R) for Relapsed Chronic Lymphocytic Leukemia (CLL): Efficacy Analysis in Patient Subpopulations with Del(17p) and Other Adverse Prognostic Factors Jeff P. Sharman, Steven Coutré, Richard R. Furman, Blood	2014	82
Resolvin D1 and aspirin-triggered resolvin D1 regulate histamine-stimulated conjunctival goblet cell secretion Daniel Li, Robin R. Hodges, Jianwei Jiao, Mucosal Immunology InflammationSignal TransductionAllergyCell SignalingImmunology	2013	80
Long-term Efficacy and Safety of OnabotulinumtoxinA in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity: An Interim Analysis Michael Kennelly, Roger R. Dmochowski, Karen Ethans, Urology	2013	77

Page 1